GlassScriptPhysician profile
Sara Sacco
NPI 1861436214
$650,724.84
in general payments reported to CMS, 2019-2025
28 companies · $76K in 2025
The $76K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113K · 2020: $80K · 2021: $134K · 2022: $102K · 2023: $56K · 2024: $89K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $153K · Honoraria: $39K · Travel and Lodging: $16K · Food and Beverage: $9,293 · Consulting Fee: $4,435 · Education: $55.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $153,285.00 |
| Honoraria | $38,574.00 |
| Travel and Lodging | $15,746.85 |
| Food and Beverage | $9,292.59 |
| Consulting Fee | $4,435.00 |
| Education | $55.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $166,223.81 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Lilly USA, LLC | $127,838.77 | 2019-2025 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $96,223.96 | 2019-2025 | Ajovy, Austedo Xr |
| Allergan, INC. | $78,425.02 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $41,366.26 | 2021 | |
| Axsome Therapeutics, INC. | $39,647.73 | 2025 | Symbravo |
| Amgen INC. | $31,378.48 | 2019-2024 | Aimovig |
| Impel Pharmaceuticals INC. | $26,115.71 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13,532.63 | 2022 | |
| Pfizer INC. | $10,539.57 | 2019-2025 | |
| Impel Pharmaceuticals LLC | $6,382.65 | 2024-2025 | Trudhesa, Trudhesa |
| Lundbeck LLC | $3,876.85 | 2019-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $3,140.09 | 2023-2025 | Ztlido |
| Biodelivery Sciences International, INC. | $1,250.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $892.30 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $850.90 | 2024-2025 | Zembrace Symtouch |
| Collegium Pharmaceutical, INC. | $810.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $489.07 | 2019-2021 | |
| Bausch Health US, LLC | $369.17 | 2019-2022 | |
| Assertio Therapeutics, INC. | $325.22 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $277.04 | 2020-2023 | |
| Almatica Pharma LLC | $206.65 | 2021-2023 | Gralise |
| Currax Pharmaceuticals LLC | $205.72 | 2020-2025 | Onzetra Xsail, Contrave |
| Idorsia Pharmaceuticals US INC | $136.61 | 2023-2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $135.85 | 2019-2025 | Brekiya |
| Azurity Pharmaceuticals, INC. | $34.99 | 2024 | Horizant |
| Zyla Life Sciences, INC. | $27.89 | 2019 | |
| Sk Life Science, INC. | $21.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Sacco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.